Rituximab as therapy for the recurrence of bile salt export pump deficiency after liver transplantation

Lin, H. C.; Alvarez, L.; Laroche, G.; Melin-Aldana, H.; Pfeifer, K.; Schwarz, K.; Whitington, P. F.; Alonso, E. M.; Ekong, U. D.

Liver Transpl. 2013 Oct 12; 19(12):1403-10

Abstract

Progressive familial intrahepatic cholestasis type 2 (PFIC2) results from recessive mutations in the adenosine triphosphate-binding cassette B11 gene, which encodes for bile salt export pump (BSEP). Liver transplantation (LT) is offered to PFIC2 patients with end-stage liver disease. Reports have described recurrent cholestasis in PFIC2 patients after transplantation, and this has been associated with immunoglobulin G antibodies to BSEP. High-titer anti-BSEP antibodies appear to correlate with episodes of cholestatic graft dysfunction. There is no established paradigm for treating antibody-mediated posttransplant BSEP disease. It appears to be refractory to changes in immunosuppressant medications that would typically be effective in treating allograft rejection. Taking what is known about its pathophysiology, we designed a treatment consisting of rituximab, a chimeric monoclonal anti-CD20 antibody, in combination with intravenous immunoglobulin and plasmapheresis. Using this approach, we report the successful management of 2 patients with antibody-mediated recurrence of PFIC2 after LT. Liver Transpl 19:1403-1410, 2013. (c) 2013 AASLD.

Read More on PubMed